Developing new vaccines to treat opioid use disorder
Official title: Nanotechnology-based platform for the development of next-generation vaccines against opioid use disorder (OUD)
Funded at University of Minnesota · NIH-10917103 · Data updated 2026-11-12
This study is exploring new vaccines to help people with opioid use disorder by reducing the risk of overdose, offering a promising alternative to current treatments that may not work well for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $36,233 |
| NIH project number | 5F31DA059235-02 |
| Project ID | NIH-10917103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking alternative treatment options.
✕Less likely to help
Patients who are not struggling with opioid use disorder or those who have not been diagnosed with substance use disorders may not benefit from this research.
What this research studies
This research focuses on creating innovative vaccines to combat opioid use disorder (OUD) and reduce the risk of overdose. By utilizing a novel nanoparticle-based platform, the project aims to enhance the effectiveness of these vaccines, which could provide a long-lasting treatment option. The approach involves understanding the molecular and cellular mechanisms that contribute to the vaccines' efficacy, with the goal of improving patient outcomes. Patients may benefit from a new alternative to current therapies that often have limited effectiveness and potential for abuse.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with opioid use disorder.
How similar studies have gone: Previous clinical trials of addiction vaccines have shown proof of efficacy, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Hamid, Fatima Alamin Awad Alkareem — University of Minnesota
- Study coordinator: Hamid, Fatima Alamin Awad Alkareem
Related research
Other NIH-funded projects on the same topics.
-
Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)
A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.
-
Precise epigenetic drugs for opioid addiction
A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.
-
Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans
This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.
-
Optimizing long-acting PrEP and opioid treatment for people in jails and prisons
This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.
-
Scaling up medications for opioid use disorder in residential treatment programs
This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.
-
Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN
This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.